Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol

Research output: Contribution to journalArticle

Abstract

Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity. Accordingly, this paper focuses on the pharmacological and therapeutic targets of these two cannabinoids. Many of the effects of Delta(9)-THC are mediated by cannabinoid receptors of which at least two types, CB1 and CB2, are present in mammalian tissues. Endogenous agonists for cannabinoid receptors have also been discovered. CB1 receptors are present at the terminals of central and peripheral neurones, where they modulate transmitter release. They also exist in some non-neuronal cells. CB2 receptors are expressed mainly by immune cells, one of their roles being to alter cytokine release. Delta(9)-THC also appears to have non-CB1, non-CB2 pharmacological targets. It is already licensed for clinical use in the U.S.A. as an anti-emetic and appetite stimulant and both Delta(9)-THC and Delta(9)-THC-rich cannabis extracts show therapeutic potential as neuroprotective and anticancer agents and for the management of glaucoma, pain and various kinds of motor dysfunction associated, for example, with multiple sclerosis and spinal cord injury. CBD has much less affinity for CB1 and CB2 receptors than Delta(9)-THC and its pharmacological actions have been less well characterized. Potential clinical applications of CBD and CBD-rich cannabis extracts include the production of anti-inflammatory and neuroprotective effects, the management of epilepsy, anxiety disorders, glaucoma and nausea, and the modulation of some effects of Delta(9)-THC.

Original languageEnglish
Pages (from-to)73-82
Number of pages10
JournalEuphytica
Volume140
Publication statusPublished - 2004

Keywords

  • cannabidiol
  • cannabinoid receptors
  • clinical applications of cannabinoids
  • pharmacological actions of cannabinoids
  • tetrahydrocannabinol
  • tolerance to cannabinoids
  • PERIPHERAL CANNABINOID RECEPTOR
  • MOUSE VAS-DEFERENS
  • NEUROPROTECTIVE ANTIOXIDANTS
  • MULTIPLE-SCLEROSIS
  • CB2 RECEPTORS
  • INHIBITION
  • ACTIVATION
  • ANANDAMIDE
  • TOLERANCE
  • AGENTS

Cite this

Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol. / Pertwee, R G .

In: Euphytica, Vol. 140, 2004, p. 73-82.

Research output: Contribution to journalArticle

@article{4d4a87e4d4f94534803d53064917f797,
title = "Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol",
abstract = "Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity. Accordingly, this paper focuses on the pharmacological and therapeutic targets of these two cannabinoids. Many of the effects of Delta(9)-THC are mediated by cannabinoid receptors of which at least two types, CB1 and CB2, are present in mammalian tissues. Endogenous agonists for cannabinoid receptors have also been discovered. CB1 receptors are present at the terminals of central and peripheral neurones, where they modulate transmitter release. They also exist in some non-neuronal cells. CB2 receptors are expressed mainly by immune cells, one of their roles being to alter cytokine release. Delta(9)-THC also appears to have non-CB1, non-CB2 pharmacological targets. It is already licensed for clinical use in the U.S.A. as an anti-emetic and appetite stimulant and both Delta(9)-THC and Delta(9)-THC-rich cannabis extracts show therapeutic potential as neuroprotective and anticancer agents and for the management of glaucoma, pain and various kinds of motor dysfunction associated, for example, with multiple sclerosis and spinal cord injury. CBD has much less affinity for CB1 and CB2 receptors than Delta(9)-THC and its pharmacological actions have been less well characterized. Potential clinical applications of CBD and CBD-rich cannabis extracts include the production of anti-inflammatory and neuroprotective effects, the management of epilepsy, anxiety disorders, glaucoma and nausea, and the modulation of some effects of Delta(9)-THC.",
keywords = "cannabidiol, cannabinoid receptors, clinical applications of cannabinoids, pharmacological actions of cannabinoids, tetrahydrocannabinol, tolerance to cannabinoids, PERIPHERAL CANNABINOID RECEPTOR, MOUSE VAS-DEFERENS, NEUROPROTECTIVE ANTIOXIDANTS, MULTIPLE-SCLEROSIS, CB2 RECEPTORS, INHIBITION, ACTIVATION, ANANDAMIDE, TOLERANCE, AGENTS",
author = "Pertwee, {R G}",
year = "2004",
language = "English",
volume = "140",
pages = "73--82",
journal = "Euphytica",
issn = "0014-2336",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Pharmacological and therapeutic targets for Delta(9)-tetrahydrocannabinol and cannabidiol

AU - Pertwee, R G

PY - 2004

Y1 - 2004

N2 - Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity. Accordingly, this paper focuses on the pharmacological and therapeutic targets of these two cannabinoids. Many of the effects of Delta(9)-THC are mediated by cannabinoid receptors of which at least two types, CB1 and CB2, are present in mammalian tissues. Endogenous agonists for cannabinoid receptors have also been discovered. CB1 receptors are present at the terminals of central and peripheral neurones, where they modulate transmitter release. They also exist in some non-neuronal cells. CB2 receptors are expressed mainly by immune cells, one of their roles being to alter cytokine release. Delta(9)-THC also appears to have non-CB1, non-CB2 pharmacological targets. It is already licensed for clinical use in the U.S.A. as an anti-emetic and appetite stimulant and both Delta(9)-THC and Delta(9)-THC-rich cannabis extracts show therapeutic potential as neuroprotective and anticancer agents and for the management of glaucoma, pain and various kinds of motor dysfunction associated, for example, with multiple sclerosis and spinal cord injury. CBD has much less affinity for CB1 and CB2 receptors than Delta(9)-THC and its pharmacological actions have been less well characterized. Potential clinical applications of CBD and CBD-rich cannabis extracts include the production of anti-inflammatory and neuroprotective effects, the management of epilepsy, anxiety disorders, glaucoma and nausea, and the modulation of some effects of Delta(9)-THC.

AB - Cannabis is the unique source of a set of at least 66 compounds known collectively as cannabinoids. Of these, most is known about the pharmacology of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive constituent of cannabis, and about cannabidiol (CBD), which lacks psychoactivity. Accordingly, this paper focuses on the pharmacological and therapeutic targets of these two cannabinoids. Many of the effects of Delta(9)-THC are mediated by cannabinoid receptors of which at least two types, CB1 and CB2, are present in mammalian tissues. Endogenous agonists for cannabinoid receptors have also been discovered. CB1 receptors are present at the terminals of central and peripheral neurones, where they modulate transmitter release. They also exist in some non-neuronal cells. CB2 receptors are expressed mainly by immune cells, one of their roles being to alter cytokine release. Delta(9)-THC also appears to have non-CB1, non-CB2 pharmacological targets. It is already licensed for clinical use in the U.S.A. as an anti-emetic and appetite stimulant and both Delta(9)-THC and Delta(9)-THC-rich cannabis extracts show therapeutic potential as neuroprotective and anticancer agents and for the management of glaucoma, pain and various kinds of motor dysfunction associated, for example, with multiple sclerosis and spinal cord injury. CBD has much less affinity for CB1 and CB2 receptors than Delta(9)-THC and its pharmacological actions have been less well characterized. Potential clinical applications of CBD and CBD-rich cannabis extracts include the production of anti-inflammatory and neuroprotective effects, the management of epilepsy, anxiety disorders, glaucoma and nausea, and the modulation of some effects of Delta(9)-THC.

KW - cannabidiol

KW - cannabinoid receptors

KW - clinical applications of cannabinoids

KW - pharmacological actions of cannabinoids

KW - tetrahydrocannabinol

KW - tolerance to cannabinoids

KW - PERIPHERAL CANNABINOID RECEPTOR

KW - MOUSE VAS-DEFERENS

KW - NEUROPROTECTIVE ANTIOXIDANTS

KW - MULTIPLE-SCLEROSIS

KW - CB2 RECEPTORS

KW - INHIBITION

KW - ACTIVATION

KW - ANANDAMIDE

KW - TOLERANCE

KW - AGENTS

M3 - Article

VL - 140

SP - 73

EP - 82

JO - Euphytica

JF - Euphytica

SN - 0014-2336

ER -